Regimen adds lab scanning, injection map and glucose tracking in version 2.2

Regimen released version 2.2 for its peptide tracker app, adding lab report scanning, a visual injection-site body map, blood glucose logging and shareable progress cards. The update is aimed at people tracking peptides, GLP-1 medications, TRT and HRT across complex dosing protocols.

Why it matters: - Regimen is targeting a gap in medication tracking for people using peptides and GLP-1s on schedules that are more complex than a once-daily pill. - The update is meant to connect dose history, labs, side effects and progress photos in one timeline, so users can see how protocol changes affect outcomes. - Regimen says more than 25,000 people use the app.

What happened: - Regimen released version 2.2 of its iPhone, Android and web app. - The app tracks peptides, GLP-1 medications, TRT and HRT. - Version 2.2 adds lab report scanning, a visual injection-site body map with per-compound rotation, blood glucose logging and shareable progress cards. - The company says the app is free to download, offers a free tier for a first compound and includes a 14-day free trial for the subscription.

The details: - Regimen already supports injection logging, custom scheduling with cycles and dose titration, peptide calculators for reconstitution and dosing, half-life tracking, injection-site rotation, supply tracking, side effects and 50+ daily markers, bloodwork, weight and health metrics, progress photos, 200+ compounds and pattern detection. - Lab report scanning in version 2.2 uploads a lab report, pulls out values and draw dates, flags out-of-range results and plots each marker against dose history. - The new body map shows where injections have been placed and suggests the next site to avoid overuse. - Users can add their own injection spots and set a separate rotation for each compound. - Blood glucose logging covers both fasted and post-meal readings. - Split dosing now supports two, three or four doses a week, each with its own day and time. - Progress cards turn photos into a shareable before-and-after format with optional weight and body fat percentage overlays. - An expanded provider report now includes adherence, current protocol with dose changes, weight and side effects from the last 90 days, all in one PDF. - Regimen says its published State of Peptide Tracking data shows about one-third of active users run more than one compound at once, most often a GLP-1 plus a peptide. - The same data shows only about one protocol in three is dosed daily. - The rest are run weekly, on set days, every few days or on a cycle. - About 14% of protocols are cycled.

Between the lines: - The product pitch is that simple reminder apps do not fit protocols involving vial reconstitution, split dosing, dose titration or cycle-based use. - Regimen is positioning data interpretation, not just logging, as the key differentiator. - The founder said the app is built to help users see what peptides or GLP-1s are actually doing for them and to separate signal from noise. - Regimen says it does not recommend compounds or doses and that user data is never sold and can be exported at any time.

What's next: - The app will continue to lean on protocol tracking, lab integration and pattern detection as more users manage multi-compound regimens. - Regimen's expanded provider report suggests the company is trying to make the app useful not just for users, but for clinicians reviewing treatment history.

The bottom line: - Regimen 2.2 turns peptide tracking into a more complete treatment log, with labs, glucose, injections and outcomes tied to the same timeline.